Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences, Inc. (Nasdaq: RNA) announced its participation in the SVB Securities Global Biopharma Conference scheduled for February 14 at 1:20 p.m. PT / 4:20 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avidity Biosciences, Inc. (Nasdaq: RNA) announced its participation in the SVB Securities Global Biopharma Conference scheduled for February 14 at 1:20 p.m. PT / 4:20 p.m. ET. The event can be accessed via a live webcast on the company's Investors page. Avidity is focused on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), aimed at treating diseases like myotonic dystrophy and facioscapulohumeral muscular dystrophy. Currently, several AOCs are undergoing clinical trials, furthering their innovative approaches in RNA therapy.
Details
News Market Reaction – RNA
The recorded move for RNA in the trading session of this news was +4.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 7, 2023 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating at the following conference:
- SVB Securities Global Biopharma Conference on February 14 at 1:20 p.m. PT/4:20 p.m. ET
A live webcast of the event, up-to-date event details and an archived replay of the webcast, will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity's proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity's advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in Phase 1/2 development with the ongoing MARINA™ and MARINA-OLE™ trials. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is currently in Phase 1/2 development with the FORTITUDE™ trial. AOC 1044 is designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping and is currently in Phase 1/2 development with the EXPLORE44™ trial. AOC 1044 is the first of multiple AOCs the company is developing for DMD. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in San Diego, CA. For more information about our science, pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and Twitter.
Investor Contact:
Kathleen Gallagher
(858) 401-7900 x550
investors@aviditybio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conference-301738721.html
SOURCE Avidity Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.